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Objectives: Becton-Dickinson recently developed the Phoenix™ CPO (carbapenemase-producing or-
ganism) Detect Test, a growth-based test embedded in Gram-negative (GN) panels for the detection and
conﬁrmation of bacteria producing class A, B and D carbapenemases. This study aimed to (a) determine
the performance of the CPO test, and (b) assess its added value in routine diagnostic workﬂows.
Methods: The performance of the BD Phoenix CPO test was analysed retrospectively on a collection of
185 molecularly characterized strains, including 92 CPOs, and prospectively on 135 and 160 routine
isolates with and without CPO suspicion, respectively.
Results: In the retrospective study the CPO test exhibited 92.4% accuracy (95%CI 87.6e95.8), 97.8%
sensitivity (95%CI 92.4e99.7) and 87.1% speciﬁcity (95%CI 78.6e93.2) for carbapenemase detection. The
CPO test provided a classiﬁcation to class A, B, and D for 81.3% of detected carbapenemases with 94.6%
accuracy (95%CI 86.7e98.5). In the prospective study the CPO test detection performance showed 77.8%
accuracy (95%CI 68.8e84.5), 100% sensitivity (95%CI 91.2e100) and 67.8% speciﬁcity (95%CI 57.3e77.1)
with 135 CPO-suspicious isolates and 98.8% accuracy and speciﬁcity (95%CI 95.6e99.9) with 160 non-
CPO-suspicious isolates. Compared to routine testing, the implementation of the CPO test allowed a
mean reduction of 21.3 h (95%CI 17.6e25) in turnaround time, 16.8 min (95%CI 13.4e20.2) in hands-on
time, and 20.6 CHF (95%CI 16.5e24.8) in costs.
Conclusions: The CPO test is reliable for the detection of CPO with a high sensitivity. However, the
relatively low detection speciﬁcity required the use of additional conﬁrmatory methods. The carba-
penemase classiﬁcation accuracy is robust in providing preliminary results before molecular character-
ization. Finally, the implementation of the test in routine workﬂows allowed a signiﬁcant reduction in
turnaround time, hands-on time and cost compared to the conventional approach. A. Croxatto, Clin
Microbiol Infect 2019;▪:1
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The emergence of carbapenemase-producing organisms (CPOs)
has triggered the development of new reliable and rapid diagnostic
tools. Upon suspicion of isolates being CPOs following initial anti-
biotic susceptibility testing (AST), phenotypic or molecular-based
methods can be used to detect and/or characterize the presence of
carbapenemases. Phenotypic tests include, among others, the Carba
NP test [1e4], the Hodge test [5,6], the carbapenem inactivationicrobiology, Department of
, Switzerland.
tto).
Ltd on behalf of European Society
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Evaluation of the BD Phoeni
doi.org/10.1016/j.cmi.2019.10method (CIM) [7], matrix-assisted laser desorption/ionization time-
of-ﬂight mass spectrometry (MALDI-TOF) [8e11], lateral ﬂow
immunoassay tests [12,13] and carbapenem disk diffusion or E-test
with and without carbapenemase inhibitors [14e17]. Depending on
the phenotypic test, the turnaround time varies from 15min to 24 h.
Some of these phenotypic testsdsuch as the NG-test Carba 5 (NG
Biotech, Guipry, France) and Carba NP testdcan be applied directly
from positive blood cultures, allowing a rapid turnaround time for
antibiotic regimen guidance [18]. Usually, the number of tests
required, turnaround time, hands-on time and costs are signiﬁcantly
higher to exclude the presence of a carbapenemase with a high
sensitivity rather than to demonstrate its activity.
The use of nucleic acid ampliﬁcation tests (NAATs) to rapidly
identify CPOs from samples such as positive blood culture andof Clinical Microbiology and Infectious Diseases. This is an open access article under
x™ CPO Detect Test for the detection of carbapenemase producers,
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empirical antibiotic therapy or for infectious control management
[19,20]. Most carbapenemase NAAT panels detect the most
frequent gene variants encoding carbapenemases, including KPC,
NDM, OXA-48, VIM and IMP. However, these tests cannot exclude
the presence of a gene encoding another carbapenemase type, and
they are relatively expensive, preventing their use in systematic
screening of some specimen types or bacterial isolates with CPO
suspicion, especially in countries where CPO prevalence is low to
very low.
Becton-Dickinson (BD, Sparks, USA) recently developed the
Phoenix CPO Detect Test, a growth-based method embedded in
Gram-negative (GN) panels for the detection and conﬁrmation of
carbapenemases of classes A, B and D [21]. This study aimed to
determine the performance of the CPO test and to investigate its
added value in routine diagnostic workﬂows. The performance of
the BD Phoenix CPO test was retrospectively and prospectively
analysed on a collection of 185 molecularly characterized strains
and on 295 routine isolates, respectively. The prospective phase
comparing the CPO test to routine testing was performed to further
determine the performance of the test and differences in turn-
around time, hands-on time and costs, including (a) 135 strains
with CPO suspicion representing an extreme diagnostic challenge,
and (b) 156 strains with no CPO suspicion representing conven-
tional isolates encountered mostly in countries with low CPO
prevalence.
Methods
Strains
The performance of the Phoenix CPO Detect Test was tested on a
collection of 92 molecularly characterized CPOs and 93 non-CPOs
(Supplementary material Table S1). The collection included 27
non-fermentative bacteria and 158 members of the Enter-
obacterales. In addition, 295 clinical isolates, including 135 isolates
suspected of carbapenemase production, were prospectively but not
consecutively isolated from various de-identiﬁed clinical specimens
during a 10-month period ranging from January to October 2018
(Supplementary material Table S2).
Phenotypic tests
All phenotypic tests were performed from bacterial colonies
growing on Columbia agar with 5% sheep blood (BD, Cat. No.
254071) or MuellereHinton agar (Oxoid Ltd, Hampshire, UK, Cat.
No. CM0337). The Carba NP test was performed as described by
Dortet et al. [4]. The CIM test was carried out as described by van
der Zwaluw et al. [7] using the susceptible Escherichia coli indicator
strain (ATCC 25922) and a 10-mg meropenem disk (Oxoid Ltd). Our
evaluation of these two phenotypic tests demonstrated an 83.9%
sensitivity and 100% speciﬁcity for the Carba NP test and a 100%
sensitivity and 100% speciﬁcity for the CIM test.
MALDI-TOF
MALDI-TOFwas used as an additional phenotypic test to exclude
the presence of carbapenamase activity in Phoenix CPO Detect Test
false positives. Hydrolysis of the meropenem test was performed as
described previously [9] except that meropenem (Labtech, Sorisole,
Italy) was used at a ﬁnal concentration of 0.5 mM. Each isolate was
tested in duplicate by spotting twice 1 mL of each replicate on a 96-
well target plate (MFX mFocus MALDI plate 96 circles, Hudson
Surface Technology, Fort Lee, USA). The matrix was composed of 1
mL of a-cyano-4-hydroxycinnamic acid (HCCA, Bruker Daltonik,Please cite this article as: Croxatto A et al., Evaluation of the BD Phoeni
Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2019.10Bremen, Germany) resuspended in 125 mL of acetonitrile þ 125 mL
of water. The MALDI-TOF was performed on a Bruker Daltonik
Microﬂex LT mass spectrometer. (A detailed description of the
spectra analysis is provided in Supplementary material.)
Phoenix CPO Detect Test
The Phoenix CPO Detect Test (BD) is a qualitative conﬁrmatory
growth-based test embedded in Gram-negative (GN) panels (NMIC-
502, NMIC-505) for detection and conﬁrmation of class A, B and D
carbapenemases. The Phoenix CPO Detect Test utilizes meropenem,
doripenem, temocillin and cloxacillin, alone and in combination
with various chelators and b-lactamase inhibitors in amounts
required for the detection and classiﬁcation of CPO. The Phoenix
CPO Detect Test was applied as described by the manufacturer.
Nucleic acid ampliﬁcation test (NAAT)
All false-positive results of the Phoenix CPO Detect Test from the
prospective study were veriﬁed by NAAT testing using the BD
MAX™ Check-Points CPO test as described by the manufacturer
(Cat. No. 278102). As described in the package insert, variants of the
carbapenemases KPC, OXA-48-like, NDM and IMP should be
detected by the BD MAX Check-Points CPO test.
Whole-genome sequencing and analysis
Bacterial strains were sub-inoculated onto BD Columbia agar
with 5% sheep blood (Cat. No. 254071), and genomic DNA was
extracted from bacterial colonies using the Wizard Genomic DNA
Puriﬁcation kit (Promega, Madison, USA, Cat. No. A1120) as
described by the manufacturer. Libraries were prepared with the
Nextera XT kit (Illumina, San Diego, USA, Cat. No. FC-131-1096) as
described by the manufacturer, and the sequencing was performed
on MiSeq (Illumina) with a paired-end 250 cycles protocol. (A
detailed description of the bioinformatics analysis is provided in
the Supplementary material.)
Laboratory workﬂow with and without Phoenix CPO Detect Test
upon suspicion of CPO
A description of the conventional routine and Phoenix CPO
Detect Test laboratoryworkﬂows upon CPO suspicion is provided in
Fig. 1. Upon CPO suspicion, the Carba NP test with an 83.9% sensi-
tivity and short turnaround time (around 2 h) was performed ﬁrst,
and the CIM test with a 100% sensitivity but a longer turnaround
time (around 1 day) was performed second to increase the sensi-
tivity of the detection.
Turnaround time, hands-on time and cost
The turnaround time, hands-on time and cost were evaluated on
the ﬁrst 114 of the 135 isolates with CPO suspicion. The total
turnaround time, hands-on time and cost for each analytical
workﬂow were obtained by summing the respective turnaround
time, hands-on time and costs of the initial AST tests and the suc-
cessive phenotypic tests that were initiated upon CPO suspicion.
The laboratory costs of the various consumables were the
following: Vitek card (AST N290 and AST N240): 8.75 CHF (7.80
EUR, 8.72 USD); Phoenix panel (NMIC-502): 8.75 CHF (7.80 EUR,
8.72 USD); carbapenems disks: 0.94 CHF (0.84 EUR, 0.94 USD);
carbapenems E-tests: 17.30 CHF (15.41 EUR, 17.24 USD); Carba NP
test: 0.90 CHF (0.80 EUR, 0.90 USD); CIM test: 0.85 CHF (0.76 EUR,
0.85 USD).x™ CPO Detect Test for the detection of carbapenemase producers,
.002
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Fig. 1. Conventional and Phoenix CPO (carbapenemase-producing organism) Detect Test laboratory workﬂows. Conventional workﬂow: at day 0, an antibiotic sensitivity test (AST)
was performed on an automated Vitek system (bioMerieux, Marcy-l’Etoile, France) with a MacConkey agar purity plate. When a CPO was suspected 1 day later (day þ1) due to
documented decreased susceptibility to at least one carbapenem drug, a subculture on blood agar of the putative CPO strain and a meropenem disk diffusion test on
MuellereHinton agar were performed and incubated 18e24 h. At day þ2, a Carba NP test was done when the meropenem disk diffusion diameter was 25 mm. A CIM test was
initiated and incubated 18e24 h following a negative Carba NP test. The CIM test was read at day þ3. Phoenix CPO Detect Test workﬂow: At day 0, an AST was performed on the
automated Phoenix M50 system with the Phoenix CPO Detect Test (panel NMIC-502) using a blood agar purity plate. At day þ1, a negative Phoenix CPO Detect Test result was
directly reported thanks to 100% sensitivity as observed in the evaluation of the performance of the Phoenix CPO Detect Test in the prospective study. When the Phoenix CPO Detect
Test was positive, a panel of conﬁrmatory tests similar to the conventional laboratory workﬂow was initiated, including reading of the Carba NP test at day þ1 and the CIM test at
day þ2. MEM, meropenem; CARBA NP, Carba NP test; CIM, CIM test.
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Retrospective performance analysis
The performance of the Phoenix CPO Detect Test to detect and to
classify carbapenemaseswas analysed on a collection of 185 strains,
including 92 molecularly characterized CPOs and 93 non-CPOs
(Supplementary material Table S1). The Phoenix CPO Detect Test
exhibited a total detection performance of 92.4% accuracy (95%CI
87.6e95.8), 97.8% sensitivity (95%CI 92.4e99.7) and 87.1% speci-
ﬁcity (95%CI 78.6e93.2) (Table 1). Two false negatives and 12 false
positives were documented (Supplementary material Table S3).
The two false negatives included an Acinetobacter pittii strain car-
rying an IMP-5-encoding gene and an E. coli strain carrying a gene
encoding OXA-181. The A. pitti IMP-5 was positive in both Carba NP
and CIM tests, whereas the E. coli OXA-181 was ‘doubtful’ in the
Carba NP and positive in the CIM tests. The genomes of the 12 false-
positive strains were sequenced and conﬁrmed to be non-CPOs, but
they contained other b-lactamase-encoding genes such as
extended-spectrum b-lactamase (ESBL) (CTX-M), AmpC cepha-
losporinases and other b-lactamase types (SHV, TEM, OXA)
(Supplementary material Table S4).
The performance of the Phoenix CPO Detect Test for carbapen-
emase classiﬁcation was assessed on the 90 detected carbapene-
mases. Among these strains, 74 were classiﬁed (82.2%) and 16Table 1
Phoenix CPO (carbapenemase-producing organism) Detect Test performance on a collec
Bacteria Total Carb pos Accuracy
n n % % 95%CI
Total 185 92 49.7 92.4 87.6e9
Enterobacterales 157 69 43.9 91.7 86.3e9
Non-fermentative 27 23 85.2 96.3 81e99.
Carb pos, carbapenemase positive; k, kappa coefﬁcient; 95%CI, 95% conﬁdence interval.
Please cite this article as: Croxatto A et al., Evaluation of the BD Phoeni
Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2019.10(17.8%) were detected but not classiﬁed (Table 2). Unclassiﬁed CPOs
included strains carrying genes encoding KPC, NDM, VIM and OXA
variants (Supplementary material Table S5).
Among the 74 classiﬁed carbapenemases, four misclassiﬁcations
were observed, giving an overall accuracy of 94.6% (95%CI
86.7e98.5) (Table 3 and Supplementary material Table S6). The
genomes of the four misclassiﬁed carbapenemase isolates were
sequenced; they all encoded carbapenemases of one or more
different classes and other b-lactamase-encoding genes
(Supplementary material Table S7).
Prospective performance analysis
The performance of the CPO detection test was evaluated pro-
spectively on 135 and 160 routine strains with and without CPO
suspicion (Supplementary material Table S2). CPO suspicion was
based on reduced susceptibility to one or more carbapenems
following routine initial AST with either automated or disk-
diffusion assays. Among the 135 routine strains with CPO suspi-
cion, 42 isolates (31.1%) were characterized as CPO strains based on
a positive Carba NP test (37 isolates), a CIM test (two isolates), and
onmolecular diagnostic with the BDmax CPE panel (three isolates).
The performance of the Phoenix CPO Detect Test on the 135
strains with CPO suspicion exhibited no false negatives but 30 false
positives, leading to a 77.8% accuracy (95%CI 68.8e84.5), 100%tion of 185 strains including 92 molecularly characterized CPOs and 93 non-CPOs
Sensitivity Speciﬁcity k
% 95%CI % 95%CI
5.8 97.8 92.4e99.7 87.1 78.6e93.2 0.85
5.5 98.6 92.2e100 86.4 77.4e92.8 0.84
9 95.7 78e99.9 100 39.8e100 0.95
x™ CPO Detect Test for the detection of carbapenemase producers,
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Table 2
Carbapenemase classiﬁcation performance of the Phoenix CPO (carbapenemase-
producing organism) Detect Test
Bacteria n Classiﬁed Unclassiﬁed
n % n %
Total 90 74 82.2 16 17.8
Enterobacterales 68 56 82.4 12 17.6
Non-fermentative 22 18 81.8 4 18.2
Classiﬁed, Phoenix-CPO-test-classiﬁed carbapenemases; Unclassiﬁed, Phoenix-
CPO-test-unclassiﬁed carbapenemases.
A. Croxatto et al. / Clinical Microbiology and Infection xxx (xxxx) xxx1.e4sensitivity (95%CI 91.2e100) and 67.8% speciﬁcity (95%CI 57.3e77.1)
(Table 4 and Supplementarymaterial Table S9). It is noteworthy that
21 of the 30 false positives (70%) were observed with Pseudomonas
aeruginosa isolates (Supplementary material Table S10). Interest-
ingly, an overall sensitivity of 100% (95%CI 91.2e100) was observed.
The absence of carbapenemase in the Phoenix CPO Detect Test
false-positive isolates were conﬁrmed by negative tests, including
Carba NP, CIM, MALDI-TOF and BDmax CPO tests.
The performance of the Phoenix CPO Detect Test on 160 routine
strains with no CPO suspicion presented two false positives (1.25%)
for an accuracy and speciﬁcity of 98.8% (95%CI 95.6e99.9)
(Supplementary material Table S8).Turnaround time, hands-on time and cost comparison
The turnaround time, hands-on time and cost were determined
for 114 strains comparing routine laboratory procedures workﬂow
with and without the implementation of the Phoenix CPO Detect
Test (Fig. 1). The implementation of the Phoenix CPO Detect Test
allowed a signiﬁcant reduction of the turnaround time and hands-
on time compared to the conventional analytical workﬂow, with an
overall cost reduction of 45% representing a mean reduction per
isolate of 20.6 CHF (18.4 EUR, 20.6 USD) (CHF 95%CI 16.5e24.8, EUR
95%CI 14.7e22.1, USD 95%CI 16.4e24.7) (Fig. 2).Discussion
Main ﬁndings
With a high sensitivity, the Phoenix CPO Detect Test is
reliable for the screening and detection of CPOs. The relatively
low detection speciﬁcity indicates that additional methods are
required to conﬁrm positive detection by the CPO test.Table 3
Performance of the Phoenix CPO (carbapenemase-producing organism) Detect Test for c
Class Truth Classiﬁed Accuracy
n n % 95%CI
A 9 10 98.7 92.7e100
B 19 18 96.0 88.6e99.2
D 46 46 94.6 86.7e98.5
Class, Ambler classiﬁcation; Truth, molecular characterization, 95%CI: 95% conﬁdence in
Table 4
Performance of the Phoenix CPO (carbapenemase-producing organism) Detect Test for c
Bacteria Total Carb pos Phoenix CPO
Detect Test
Accura
N N % N N FP %
Total 135 42 31.1 72 30 77.8
Enterobacterales 85 29 34.1 38 9 89.4
Non fermentative 50 13 26.0 34 21 58
Carb pos: Carbapenemase positive (truth), Phoenix CPO Detect Test: N of Phoenix CPO D
N: Number of strains, %: Percentage, 95% CI: 95% conﬁdence interval.
Please cite this article as: Croxatto A et al., Evaluation of the BD Phoeni
Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2019.10However, the prospective study on routine isolates with no CPO
suspicion showed a 98.8% speciﬁcity (95%CI 95.6e99.9), indi-
cating that the number of conﬁrmatory tests will be minimal in
routine diagnostic laboratories with a low CPO suspicion
prevalence. As with any other phenotypic test, the speciﬁcity of
the Phoenix CPO Detect Test will strongly depend on the
phenotype of the non-CPO, with an expected decreased speci-
ﬁcity with highly challenging isolates combining ESBLs and/or
AmpCs with porin loss [21].
The carbapenemase classiﬁcation providing 94.6% accuracy (95%
CI 86.7e98.5) is robust in reporting preliminary results before
molecular characterization. Finally, the implementation of the
Phoenix CPO Detect Test in routine practice allows a signiﬁcant
reduction in turnaround time, hands-on time and cost compared to
the conventional approach (Fig. 2).Strengths and weaknesses
The retrospective and prospective studies showed only two false
negatives (1.48%) and 44 false positives (12.7%). The two false-
negative strains were positive with other phenotypic tests,
excluding the possibility of an absence of expression and/or activity
of these carbapenemases. However, low-level carbapenemase
expression and/or growth impairment due to a carbapenemase-
independent mechanism may have prevented their detection by
the Phoenix CPO Detect Test.
Among the 90 detected carbapenemases, 70 were correctly
classiﬁed, 16 were not classiﬁed and four were misclassiﬁed by the
Phoenix CPO Detect Test (Supplementary material Table S6).
Phenotypic detection and classiﬁcation of strains carrying multiple
carbapenemase types, ESBL, AmpC and potentially other unchar-
acterized carbapenemase resistance mechanisms is difﬁcult due
the coexistence of different resistance mechanisms that prevent
phenotypic detection and classiﬁcation by combinations of anti-
biotic and b-lactamase inhibitors. For instance, the failure to detect
alternative carbapenemase classes or ESBL and AmpC with porin
loss may lead to false-positive detection of class D OXA-48 types if,
in addition, decreased susceptibility and/or natural resistance to
carbapenems other than ertapenem and temocillin are observed.
For instance, the natural resistance of P. aeruginosa to both erta-
penem and temocillin may signiﬁcantly interfere with the carba-
penemase classiﬁcation performance of the CPO Detect Test.
Moreover, hyperproduction of AmpC cephalosporinase may bearbapenemase Ambler classiﬁcation
Sensitivity Speciﬁcity
% 95%CI % 95%CI
100.0 66.4e100 98.5 91.8e100
89.5 66.9e98.7 98.2 90.3e100
95.7 85.2e99.5 92.9 76.5e99.1
terval.
arbapenemase detection on 135 strains with CPO suspicion
cy Sensitivity Speciﬁcity k
95% CI % 95% CI % 95% CI
68.8e84.5 100 91.2e100 67.7 57.3e77.1 0.31
80.9e95 100 88.1e100 84 71.7e92.4 0.53
43.2e71.8 100 75.3e100 43.2 27.1e60.5 0.13
etect Test CPO positive results, N FP: Number of false positives, k: Kappa coefﬁcient,
x™ CPO Detect Test for the detection of carbapenemase producers,
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Fig. 2. (A) Turnaround time to conﬁrm or exclude the presence of a carbapenemase-producing organism (CPO). By using the Phoenix CPO Detect Test, the turnaround time per test
could be decreased by a mean 19.4 h (95%CI 13.9e24.9) for negative CPOs (p < 0.0001), a mean 21.5 h (95%CI 16.4e26.5) for positive CPOs (p < 0.0001) and a mean 21.3 h (95%CI
17.6e25) for combined negative and positive CPOs. (B) Hands-on time to perform all the phenotypic test required to conﬁrm or exclude the presence of a CPO, including the initial
AST tests (Vitek or Phoenix M50). By using the Phoenix CPO Detect Test, the hands-on time per test could be decreased by a mean 17 min (95%CI 12e22.1) for negative CPOs
(p < 0.0001), a mean 15.3 min (95%CI 10.7e19.9) for positive CPOs (p < 0.0001) and a mean 16.8 min (95%CI 13.4e20.2) for combined negative and positive CPOs. (C) Hands-on time
and cost of consumables to perform the phenotypic tests required to conﬁrm or exclude the presence of a CPO. By using the Phoenix CPO Detect Test, the total cost was decreased by
a mean 20.6 CHF (95%CI 14.4e26.8) (18.3 EUR: 95%CI 12.8e23.8, 20.5 USD: 95%CI 14.3e26.7) for negative CPOs (p < 0.0001), a mean 19.0 CHF (95%CI 13.4e24.7) (17.0 EUR: 95%CI
11.9e22, 19.0 USD: 95%CI 13.3e24.6) for positive CPOs (p < 0.0001) and a mean 20.6 CHF (95%CI 16.5e24.8) (18.4 EUR: 95%CI 14.7e22.1, 20.6 USD: 95%CI 16.4e24.7) for combined
negative and positive CPOs (p < 0.0001). (D) Sum of the hands-on time and cost of consumables for 114 analysed strains with CPO suspicion. A cost saving of 45% was observed
following the introduction of the Phoenix CPO Detect Test. The p values have been calculated using the Tukey's multiple comparison test (Graphpad Prism 7.0); p  0.01 (**),
p  0.001 (***), p  0.0001 (****).
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hibition with cloxacillin is not documented.
The high sensitivity observed in this study (Tables 1 and 4)
allowed direct reporting of CPO-negative strains without additional
tests, signiﬁcantly decreasing the turnaround time, hands-on time
and cost. Despite a moderate speciﬁcity, a signiﬁcant gain of turn-
around time, hands-on time and costs compared to the conven-
tional approach was also observed with positive Phoenix CPO
Detect Tests. This results mainly from (a) Phoenix panels that, un-
like the Vitek cards currently used in our laboratory, directly
provide true carbapenem MICs that can be used as carbapenemase
screening values, and (b) the replacement of MacConkey by blood
agar purity plates allowing the execution of additional conﬁrma-
tion tests 24 h earlier (Fig. 1). In countries with a low CPO preva-
lence and poor positive predictive value (PPV), additional tests for
carbapenemase detection and classiﬁcation [1,22,23] are initiated
only if the MIC values or disk diffusion inhibition zones are above
the screening cut-off value [24] to reduce the hands-on time and
cost of unnecessary phenotypic and molecular tests for CPO
detection and classiﬁcation.Limitations
Because of a very low CPO prevalence, the prospective studywas
not performed on consecutive routine isolates but on 135 selected
isolates with CPO suspicion representing an extreme diagnostic
challenge and on 156 isolates with no CPO suspicion representing
conventional isolates mostly encountered in countries with very
low CPO prevalence. The results presented in the prospective study
are thus biased by the selection criteria used to collect these two
groups of isolates. The true performance of the Phoenix CPO Detect
Test in a context of low and high CPO prevalence remains to be
assessed by the implementation of this test in routine diagnostic
laboratories.
It should be noted that the signiﬁcant decrease in turnaround
time, hands-on time and costs observed in this study with the
Phoenix CPO Detect Test totally rely on comparison with the con-
ventional laboratory workﬂow for CPO detection as implemented
in our laboratory, which is especially adapted to countries with low
CPO prevalence. The result may differ greatly with alternative
analytical workﬂows setups, including direct molecular and
phenotypic testing with rapid carbapenemase detection and clas-
siﬁcation assays [12,13]. The analytical workﬂow in countries with
high CPO prevalence may include direct conﬁrmatory phenotypic
and molecular testing upon CPO suspicion following AST or from
samples such as positive blood cultures to signiﬁcantly reduce the
turnaround time [18,20]. On the other hand, high-prevalence
countries may also exhibit lower negative predictive value (NPV),
thus requiring additional tests to exclude the presence of a CPO
with a high probability.Implications
The signiﬁcantly decreased turnaround time observed with the
Phoenix CPO Detect Test may have a positive impact on therapeutic
and infection control decisions, including antibiotic de-escalation
and escalation as well as costly patient isolation measures. Rapid
detection and classiﬁcation of CPOs is essential to avoid treatment
failures with poor outcomes and to guide empirical antibiotic
therapy as, for instance, class A CPOs can potentially be treatedwith
ceftazidime/avibactam. The Phoenix CPO Detect Test panels also
provide useful information for infection control surveillance since
patients both at risk and not at risk are automatically screened for
CPOs.Please cite this article as: Croxatto A et al., Evaluation of the BD Phoeni
Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2019.10Conclusions
The Phoenix CPO Detect Test likely represents a new diagnostic
tool with added value for the detection and management of CPO
infection and colonization. The CPO test is reliable for the detection
of CPOs with a high sensitivity, but the relatively low speciﬁcity
requires the use of additional conﬁrmatory methods. The carba-
penemase classiﬁcation accuracy is robust in providing preliminary
results before molecular characterization. Finally, the imple-
mentation of the test in routine workﬂows allows a signiﬁcant
reduction in turnaround time, hands-on time and cost compared to
the conventional approach. Overall, the implementation of the
Phoenix CPO Detect Test may have a positive impact on laboratory
workﬂows but also on therapeutic and infection control decisions.
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